Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Squalamine phosphate
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Enterin’s oral lead compound, ENT-01 which prevents alpha synuclein from accumulating and aggregating within the enteric nervous system, receives FDA acceptance of an investigator sponsored IND application to treat a patient with prodromal multisystem ...
Product Name : ENT-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 31, 2023
Lead Product(s) : Squalamine phosphate
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ENT-03
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Enterin Announces the Start of a First-in-Human Study of ENT-03 in Obesity and Type 2 Diabetes
Details : ENT-03 is a novel, endogenous, centrally acting aminosterol with protein tyrosine phosphatase 1B (PTP1B) inhibitory activity, which normalizes glucose and causes weight loss by acting on brain circuits that regulate energy and metabolism in Obesity and T...
Product Name : ENT-03
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 06, 2023
Lead Product(s) : ENT-03
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Squalamine phosphate
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Parkinson’s Virtual Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
Enterin and Parkinson’s UK Announce Research Collaboration in Parkinson’s Dementia
Details : ENT-01 is administered orally and acts locally on the ENS. It dislodges αS aggregates and inhibits their formation, restoring the firing potential of enteric neurons.
Product Name : ENT-01
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 13, 2022
Lead Product(s) : Squalamine phosphate
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Parkinson’s Virtual Biotech
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Squalamine phosphate
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Enterin to Present at Chardan's Virtual 3rd Annual Microbiome Medicines Summit
Details : Dr. Denise Barbut, Enterin's co-founder and CMO, will present the company's latest updates relating to its lead compound, ENT-01, which is currently being developed for the treatment of Parkinson's Disease (PD).
Product Name : ENT-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 03, 2021
Lead Product(s) : Squalamine phosphate
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COV-ENT-1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Enterin to Conduct a Randomized Phase 1/2a Study in Hospitalized Patients With COVID-19
Details : COV-ENT-1 has been shown to have broad-spectrum antiviral activity against both RNA and DNA viruses, both in vitro and in vivo, in studies supported by the NIAID.
Product Name : COV-ENT-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 17, 2020
Lead Product(s) : COV-ENT-1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable